Edition:
India

Syros Pharmaceuticals Inc (SYRS.OQ)

SYRS.OQ on NASDAQ Stock Exchange Global Select Market

10.09USD
16 Feb 2018
Change (% chg)

$-0.17 (-1.66%)
Prev Close
$10.26
Open
$10.29
Day's High
$10.57
Day's Low
$9.94
Volume
65,097
Avg. Vol
103,332
52-wk High
$24.35
52-wk Low
$6.31

Chart for

About

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments... (more)

Overall

Beta: --
Market Cap(Mil.): $420.43
Shares Outstanding(Mil.): 26.26
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Syros Pharmaceuticals Enters Amendment To Stock Purchase Agreement With Incyte

* SYROS PHARMACEUTICALS -‍ ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING​

31 Jan 2018

BRIEF-Syros Prices Public Offering Of 4.19 Mln Common Shares At $9.55/Share

* SYROS ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING OF COMMON STOCK

31 Jan 2018

BRIEF-Syros Announces Proposed Offering Of Common Stock

* SYROS PHARMACEUTICALS INC - ‍OFFERING TO SELL $40.0 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING​ Source text for Eikon: Further company coverage:

31 Jan 2018

BRIEF-Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement

* INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT

08 Jan 2018

BRIEF-Syros Announces 2018 Strategic Priorities And Expected Milestones

* SYROS ANNOUNCES 2018 STRATEGIC PRIORITIES AND EXPECTED MILESTONES

08 Jan 2018

BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425

* SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS

02 Jan 2018

BRIEF-Syros Pharma Q3 loss per share $0.53

* Syros reports third quarter 2017 financial results and highlights accomplishments and upcoming milestones

08 Nov 2017

BRIEF-SYROS PHARMACEUTICALS PRESENTS BIOMARKER DATA FROM ONGOING PHASE 2 TRIAL OF SY-1425

* SYROS PHARMACEUTICALS INC - PRESENTS BIOMARKER DATA FROM ITS ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425 IN GENOMICALLY DEFINED AML AND MDS PATIENTS

05 Oct 2017

BRIEF-Syros Pharmaceuticals says board appointed CEO Nancy Simonian as company's principal financial officer - SEC Filing

* Syros Pharmaceuticals says on Sept 28 board appointed Nancy Simonian, co's president and CEO, as company's principal financial officer - SEC Filing Source text: [http://bit.ly/2hAgfq3] Further company coverage:

30 Sep 2017

BRIEF-Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​

* Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​ Source text for Eikon: Further company coverage:

11 Sep 2017

Earnings vs. Estimates